Cash flow Sana Biotechnology, Inc.

Stocks

SANA

US7995661045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:23:34 11/06/2026 pm IST			5-day change	1st Jan Change
2.835 ^USD	+0.53%		-4.05%	-30.22%

10/06	Sana Biotechnology, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04:00 PM
15/05	Sana Biotechnology Raises $69 Million Through ATM Equity Offering	MT

e14c2eb4c613e14a.7zagLfCz4ueF7Yx-g0IC-kcVwiJia0OslCwOwmaJAlo.nkDUfYXi17TEq7QmwgB4vhhBtUkoLA7c_BtChTewUSKFfJJmh-SDlMS06w

Published financial data: SANA BIOTECHNOLOGY, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Selling General & Admin Expenses, Total	5.04Cr	6.71Cr	7.33Cr	6.4Cr	4.43Cr
R&D Expenses	27Cr	20Cr	25Cr	21Cr	15Cr
Other Operating Expenses, Total	33Cr	27Cr	33Cr	27Cr	19Cr
Operating Income	-33Cr	-27Cr	-33Cr	-27Cr	-19Cr
Interest And Investment Income	7L	37.62L	99.38L	1.05Cr	38.48L
Net Interest Expenses	7L	37.62L	99.38L	1.05Cr	38.48L
Other Non Operating Income (Expenses)	3L	-7L	-52T	-	46.05L
EBT, Excl. Unusual Items	-32Cr	-27Cr	-32Cr	-26Cr	-18Cr
Merger & Related Restructuring Charges	-	-	-	-	-
Asset Writedown	-	-45L	-70.14L	-63.98L	-4.69Cr
Other Unusual Items	-3.18Cr	33.64L	4.08Cr	6L	-1.48Cr
EBT, Incl. Unusual Items	-36Cr	-27Cr	-28Cr	-27Cr	-24Cr
Income Tax Expense	-	-	-	-	-
Earnings From Continuing Operations	-36Cr	-27Cr	-28Cr	-27Cr	-24Cr
Net Income to Company	-36Cr	-27Cr	-28Cr	-27Cr	-24Cr
Net Income - (IS)	-36Cr	-27Cr	-28Cr	-27Cr	-24Cr
Net Income to Common Incl Extra Items	-36Cr	-27Cr	-28Cr	-27Cr	-24Cr
Net Income to Common Excl. Extra Items	-36Cr	-27Cr	-28Cr	-27Cr	-24Cr
Per Share Items
Net EPS - Basic	-2.14	-1.43	-1.46	-1.16	-0.96
Basic EPS - Continuing Operations	-2.14	-1.43	-1.46	-1.16	-0.96
Basic Weighted Average Shares Outstanding	17Cr	19Cr	19Cr	23Cr	25Cr
Net EPS - Diluted	-2.14	-1.43	-1.46	-1.16	-0.96
Diluted EPS - Continuing Operations	-2.14	-1.43	-1.46	-1.16	-0.96
Diluted Weighted Average Shares Outstanding	17Cr	19Cr	19Cr	23Cr	25Cr
Normalized Basic EPS	-1.22	-0.89	-1.02	-0.71	-0.45
Normalized Diluted EPS	-1.22	-0.89	-1.02	-0.71	-0.45
Supplemental Items
EBITDA	-31Cr	-26Cr	-30Cr	-26Cr	-18Cr
EBITA	-33Cr	-27Cr	-33Cr	-27Cr	-19Cr
EBIT	-33Cr	-27Cr	-33Cr	-27Cr	-19Cr
EBITDAR	-29Cr	-22Cr	-27Cr	-22Cr	-14Cr
Effective Tax Rate - (Ratio)	-	-	-	-	-
Total Deferred Taxes	-	-	-	-	-
Normalized Net Income	-20Cr	-17Cr	-20Cr	-16Cr	-11Cr
Supplemental Operating Expense Items
General and Administrative Expenses	5.04Cr	6.71Cr	7.33Cr	6.4Cr	4.43Cr
Research And Development Expense From Footnotes	31Cr	20Cr	22Cr	21Cr	16Cr
Net Rental Expense, Total	2.22Cr	3.11Cr	3.48Cr	3.17Cr	3.7Cr
Stock-Based Comp., R&D Exp. (Total)	1.52Cr	2.66Cr	2.32Cr	2.34Cr	1.52Cr
Stock-Based Comp., G&A Exp. (Total)	71.23L	1.18Cr	1.23Cr	1.43Cr	1.03Cr
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	2.24Cr	3.83Cr	3.55Cr	3.77Cr	2.55Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	25Cr	18Cr	13Cr	13Cr	7.19Cr
Short Term Investments	30Cr	25Cr	7.17Cr	2.49Cr	6.65Cr
Total Cash And Short Term Investments	55Cr	42Cr	21Cr	15Cr	14Cr
Prepaid Expenses	71.05L	1.44Cr	44.88L	44.79L	60.99L
Restricted Cash	-	61L	38.32L	38.32L	41.95L
Other Current Assets, Total	-	-	-	-	-
Total Current Assets	56Cr	44Cr	21Cr	16Cr	15Cr
Gross Property Plant And Equipment	18Cr	19Cr	19Cr	19Cr	12Cr
Accumulated Depreciation	-1.88Cr	-3.4Cr	-4.18Cr	-5.42Cr	-5.48Cr
Net Property Plant And Equipment	16Cr	16Cr	15Cr	14Cr	6.52Cr
Long-term Investments	20Cr	1.01Cr	-	-	-
Goodwill	14Cr	14Cr	14Cr	14Cr	14Cr
Other Intangibles, Total	5.92Cr	5.92Cr	5.92Cr	5.92Cr	5.92Cr
Other Long-Term Assets, Total	1.38Cr	90.07L	63.7L	51.21L	31.73L
Total Assets	112.94Cr	82Cr	57Cr	50Cr	42Cr
Liabilities
Accounts Payable, Total	22.19L	28.57L	41.08L	52.1L	16.69L
Accrued Expenses, Total	2.89Cr	3.91Cr	3.8Cr	2.74Cr	2.15Cr
Current Portion of Leases	91.59L	1.24Cr	1.32Cr	1.28Cr	1.53Cr
Other Current Liabilities	5.89Cr	5.71Cr	92L	-	4.02Cr
Total Current Liabilities	9.92Cr	11Cr	6.45Cr	4.54Cr	7.87Cr
Long-Term Leases	10Cr	9.59Cr	9.09Cr	8.91Cr	7.09Cr
Other Non Current Liabilities	20Cr	12Cr	12Cr	12Cr	11Cr
Total Liabilities	40Cr	32Cr	28Cr	25Cr	26Cr
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	18T	19T	20T	22T	27T
Additional Paid In Capital	151.52Cr	155.85Cr	162.56Cr	185.53Cr	200.98Cr
Retained Earnings	-79Cr	-105.48Cr	-133.81Cr	-160.48Cr	-184.9Cr
Comprehensive Income and Other	-13.66L	-43.27L	-60T	14T	28T
Total Common Equity	73Cr	50Cr	29Cr	25Cr	16Cr
Total Equity	73Cr	50Cr	29Cr	25Cr	16Cr
Total Liabilities And Equity	112.94Cr	82Cr	57Cr	50Cr	42Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	19Cr	19Cr	22Cr	23Cr	27Cr
ECS Total Common Shares Outstanding	18Cr	19Cr	20Cr	22Cr	27Cr
Book Value / Share	3.94	2.61	1.45	1.12	0.6
Tangible Book Value	53Cr	30Cr	8.77Cr	5.07Cr	-3.89Cr
Tangible Book Value Per Share	2.86	1.57	0.44	0.23	-0.15
Total Debt	11Cr	11Cr	10Cr	10Cr	8.63Cr
Net Debt	-64Cr	-33Cr	-10Cr	-5.06Cr	-5.21Cr
Debt Equivalent Oper. Leases	18Cr	25Cr	28Cr	25Cr	30Cr
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	4.9Cr	6.48Cr	5.48Cr	5.78Cr	4.26Cr
Full Time Employees	383	418	328	194	142
Part Time Employees	3	3	-	-	-

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-36Cr	-27Cr	-28Cr	-27Cr	-24Cr
Depreciation & Amortization - CF	1.11Cr	1.56Cr	2.46Cr	1.55Cr	1.28Cr
Depreciation & Amortization, Total	1.11Cr	1.56Cr	2.46Cr	1.55Cr	1.28Cr
Asset Writedown & Restructuring Costs	-	-	-	18.91L	4.46Cr
Stock-Based Compensation (CF)	2.24Cr	3.83Cr	3.55Cr	3.77Cr	2.55Cr
Other Operating Activities, Total	6.16Cr	-8.21Cr	-4.9Cr	-1.03Cr	2.76Cr
Change In Accounts Payable	-3L	10.58L	10.27L	13.77L	-35.45L
Change in Other Net Operating Assets	1.01Cr	64.84L	1.76Cr	-25.62L	-65.69L
Cash from Operations	-25Cr	-29Cr	-25Cr	-22Cr	-14Cr
Capital Expenditure	-2.99Cr	-2.09Cr	-2Cr	-3.34Cr	-9L
Sale of Property, Plant, and Equipment	-	-	-	-	14.32L
Cash Acquisitions	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-21Cr	23Cr	19Cr	5.09Cr	-4.07Cr
Other Investing Activities, Total	-45.74L	-	-	-	-
Cash from Investing	-25Cr	21Cr	17Cr	1.75Cr	-4.02Cr
Long-Term Debt Issued, Total	-	-	-	77.44L	-
Total Debt Issued	-	-	-	77.44L	-
Long-Term Debt Repaid, Total	-	-	-	-	-3L
Total Debt Repaid	-	-	-	-	-3L
Issuance of Common Stock	63Cr	49.13L	3.16Cr	19Cr	13Cr
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-	-	-	-	-
Cash from Financing	63Cr	49.13L	3.16Cr	20Cr	13Cr
Net Change in Cash	13Cr	-7.46Cr	-4.99Cr	-59.51L	-5.53Cr
Supplemental Items
Levered Free Cash Flow	-14Cr	-14Cr	-20Cr	-17Cr	-5.36Cr
Unlevered Free Cash Flow	-14Cr	-14Cr	-20Cr	-17Cr	-5.36Cr
Change In Net Working Capital	-6.14Cr	43.34L	3.57Cr	1.87Cr	-2.85Cr
Net Debt Issued / Repaid	-	-	-	77.44L	-3L

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-21.85	-17.38	-29.44	-31.82	-26
Return on Total Capital	-30.25	-23.45	-40.9	-45.61	-40.33
Return On Equity %	-61.36	-43.9	-72	-99.16	-118.7
Return on Common Equity	-231.63	-43.9	-72	-99.16	-118.7
Short Term Liquidity
Current Ratio	5.62	3.99	3.31	3.54	1.89
Quick Ratio	5.55	3.8	3.18	3.36	1.76
Operating Cash Flow to Current Liabilities	-2.53	-2.6	-3.93	-4.91	-1.83
Long Term Solvency
Total Debt/Equity	15.23	21.68	36.21	40.68	53.62
Total Debt / Total Capital	13.22	17.82	26.58	28.92	34.9
LT Debt/Equity	13.97	19.2	31.62	35.55	44.08
Long-Term Debt / Total Capital	12.13	15.78	23.21	25.27	28.7
Total Liabilities / Total Assets	35.5	39.31	49.14	50	61.41
Total Debt / EBITDA	-0.38	-0.48	-0.39	-0.45	-0.61
Net Debt / EBITDA	2.18	1.45	0.38	0.23	0.37
Total Debt / (EBITDA - Capex)	-0.34	-0.44	-0.36	-0.4	-0.61
Net Debt / (EBITDA - Capex)	1.98	1.33	0.35	0.2	0.37
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	38.06	-18.53	22.36	-17.26	-30.38
EBITA, 1 Yr. Growth %	39.3	-16.5	24.43	-16.96	-29.66
EBIT, 1 Yr. Growth %	39.3	-16.5	24.43	-16.96	-29.66
Earnings From Cont. Operations, 1 Yr. Growth %	24.75	-24.29	5.11	-5.82	-8.47
Net Income, 1 Yr. Growth %	24.75	-24.29	5.11	-5.82	-8.47
Normalized Net Income, 1 Yr. Growth %	39.38	-17.2	22.1	-17.67	-30.08
Diluted EPS Before Extra, 1 Yr. Growth %	-90.25	-33.1	1.76	-20.65	-16.55
Net Property, Plant and Equip., 1 Yr. Growth %	47.15	-1.47	-8.66	-7.09	-51.79
Total Assets, 1 Yr. Growth %	54.65	-27.15	-31.29	-11.37	-16.79
Tangible Book Value, 1 Yr. Growth %	-185.13	-43.35	-70.72	-42.2	-176.83
Common Equity, 1 Yr. Growth %	-272.97	-31.46	-42.42	-12.87	-35.78
Cash From Operations, 1 Yr. Growth %	81.95	15.53	-12.57	-12	-35.55
Capital Expenditures, 1 Yr. Growth %	25.09	-30.09	-4.04	66.88	-97.19
Levered Free Cash Flow, 1 Yr. Growth %	-7.36	1.97	47.59	-18.52	-68.17
Unlevered Free Cash Flow, 1 Yr. Growth %	-7.36	1.97	47.59	-18.52	-68.17
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	60.78	0.27	-1.87	0.03	-24.1
EBITA, 2 Yr. CAGR %	62.37	2.1	0.28	0.01	-23.57
EBIT, 2 Yr. CAGR %	62.37	2.1	0.28	0.01	-23.57
Earnings From Cont. Operations, 2 Yr. CAGR %	64.97	-2.81	-10.79	-0.51	-7.16
Net Income, 2 Yr. CAGR %	64.97	-2.81	-10.79	-0.51	-7.16
Normalized Net Income, 2 Yr. CAGR %	64.02	1.69	-1.1	-1.38	-24.13
Diluted EPS Before Extra, 2 Yr. CAGR %	-71.68	-74.45	-17.49	-10.14	-18.62
Net Property, Plant and Equip., 2 Yr. CAGR %	53.34	20.41	-5.14	-7.88	-33.07
Total Assets, 2 Yr. CAGR %	64.93	6.14	-29.25	-21.96	-14.12
Tangible Book Value, 2 Yr. CAGR %	24.27	-30.55	-59.27	-58.86	-33.36
Common Equity, 2 Yr. CAGR %	126.07	8.88	-37.18	-29.17	-25.19
Cash From Operations, 2 Yr. CAGR %	71.34	44.99	0.5	-12.29	-24.69
Capital Expenditures, 2 Yr. CAGR %	6.92	-6.49	-18.1	26.54	-78.36
Levered Free Cash Flow, 2 Yr. CAGR %	26.03	-7.88	20.29	9.39	-49.12
Unlevered Free Cash Flow, 2 Yr. CAGR %	26.03	-7.88	20.29	9.39	-49.12
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	128.01	28.18	5.92	-6.58	-11.35
EBITA, 3 Yr. CAGR %	130.65	30.09	7.88	-5.83	-11.06
EBIT, 3 Yr. CAGR %	130.65	30.09	7.88	-5.83	-11.06
Earnings From Cont. Operations, 3 Yr. CAGR %	137.72	27.25	-0.24	-9.17	-3.23
Net Income, 3 Yr. CAGR %	137.72	27.25	-0.24	-9.17	-3.23
Normalized Net Income, 3 Yr. CAGR %	130.41	30.6	6.9	-6.96	-12.06
Diluted EPS Before Extra, 3 Yr. CAGR %	-57.49	-62.29	-59.5	-18.56	-12.33
Net Property, Plant and Equip., 3 Yr. CAGR %	551.52	32.32	9.81	-5.79	-25.76
Total Assets, 3 Yr. CAGR %	220.42	25.6	-8.18	-23.73	-20.28
Tangible Book Value, 3 Yr. CAGR %	242.25	-4.36	-47.93	-54.23	-49.34
Common Equity, 3 Yr. CAGR %	280.85	51.87	-11.95	-29.94	-31.44
Cash From Operations, 3 Yr. CAGR %	110.31	50.25	22.49	-3.85	-20.85
Capital Expenditures, 3 Yr. CAGR %	218.99	-7.2	-5.68	3.83	-64.45
Levered Free Cash Flow, 3 Yr. CAGR %	-	17.44	6.39	6.86	-27.56
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	17.44	6.39	6.86	-27.56
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	62.74	16.08	-6.87
EBITA, 5 Yr. CAGR %	-	-	65.3	17.1	-6.01
EBIT, 5 Yr. CAGR %	-	-	65.3	17.1	-6.01
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	60.62	15.32	-3.07
Net Income, 5 Yr. CAGR %	-	-	60.62	15.32	-3.07
Normalized Net Income, 5 Yr. CAGR %	-	-	64.28	16.72	-6.8
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-44.57	-46.63	-46.46
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	201.44	14.48	-9.92
Total Assets, 5 Yr. CAGR %	-	-	75.11	3.83	-10.61
Tangible Book Value, 5 Yr. CAGR %	-	-	46.07	-31.75	-42.53
Common Equity, 5 Yr. CAGR %	-	-	85.22	11.94	-17.51
Cash From Operations, 5 Yr. CAGR %	-	-	56.52	21.15	0.83
Capital Expenditures, 5 Yr. CAGR %	-	-	85.18	5.06	-47.66
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	14.15	-20.25
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	14.15	-20.25